

## CURRICULUM VITAE

October 1<sup>st</sup> 2013

François Mach (born on 25<sup>th</sup> September 1961)

POSITION TITLE

Head of Cardiology Division,  
University of Geneva

Professor, MD

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Univ. of Geneva, Medical School		1982-1989	Medicine
Dept. Internal Medicine, Aigle Hospital	MD, Dr. med.	1989-1990	Internal Medicine
Dept. Internal Medicine, Univ. Hospital Geneva	MD, Dr. med.	1990-1993	Internal Medicine
		1993-1995	Cardiology
Dept. Medicine, Brigham and Women's Hospital, Boston	MD, Dr. med.	1995-1999	Vascular Biology
Dept. Internal Medicine, Cardiology, Univ. Geneva	MD, Dr. med.	1999-2005	Cardiovascular Biology
Geneva University Hospital, Good Clinical Practice (GCP) course	GCP Certificate	2011	Clinical Research

**Date and Place of Birth:** September 25, 1961, in New-York

**Marital status, children:** Married, 3 children.

**Private Address:** Chemin de Petray 24, 1222 Vézenaz/Geneva. Tel: +41 22 752 01 17.

**Professional Address:** Service de Cardiologie, Département de Médecine Interne,  
Université de Genève, rue Gabrielle-Perret-Gentil 4, CH-1211 Genève 14. Tel:+41 22 372  
71 92. Fax:+41 22 372 72 45. E-mail: [Francois.Mach@hcuge.ch](mailto:Francois.Mach@hcuge.ch)

### A. Positions and Honors.

1989-1990	Resident in Internal Medicine Aigle Hospital, Aigle Switzerland
1990-1992	Clinical Fellow, Division of Internal Medicine, Geneva University Hospital
1992-1993	Senior Fellow, Division of Internal Medicine, Geneva University Hospital
1993-1995	Resident, Division of Cardiology, Geneva University Hospital
1995-1998	Research Fellow, Vascular Medicine and Atherosclerosis Unit, Department of Medicine, Division of Cardiovascular, Brigham and Women's Hospital, Boston USA
1999-2005	Principal Investigator Program SCORE A, Swiss National Research Foundation, cardiovascular research laboratory, and consultant for cardiology, Division of Cardiology, Geneva University Hospital
2004-2006	Associate Professor, Faculty of Medicine, Geneva University
2006-present	Full Professor of Cardiology, Head of Cardiology Department, Geneva University Hospital
1984	Crew-member of the sailing boat "UBS Switzerland" winner of the race around the world 1984-1985
1999	Cardio-Vascular-Biology Prize
2000	Swiss Society of Cardiology Prize
2000	Leenaards Prize
2002	Pfizer Research Prize
2007	Prof. Max Cloëtta Prize
1995	Member of the Swiss Society of Cardiology
2000	Member of the European Society of Cardiology

2000	Member of the American Heart Association Scientific Council
2001	Councillor of the European Society of Clinical Investigation
2008	Member of the AtheroRemo Network
2009	Invited Editor of Seminars in Immunopathology; Section Editor of Thrombosis and Haemostasis
2010	Invited Editor of Current Pharmaceutical Biotechnology
2012	President of Swiss Society of Cardiology

## **B. Research Support.**

- Research grant: Role of Vascular Wall Chemokines in the Pathogenesis of Atherosclerosis. Swiss National Science Foundation, 1999 - 2001. Responsibility: Project leader.
- Research grant: A new role for HMG-CoA reductase inhibitors (Statins) and PPAR activators as potential new anti-inflammatory agents. Swiss National Science Foundation, 2002 - 2004. Responsibility: Project leader.
- Research grant: Fondation Leenaards. Role of chemokines, gap junctions and adhesion molecules in leukocyte recruitment during early stage of atherosclerosis. Investigation by modulation of endothelium dysfunction in an ex vivo arterial vascular model. 2000-2003. Responsibility: Project leader.
- Research grant: "European Vascular Biology Network EVGN" Sixth Framework Program Theme FP6 European Network of Excellence Program -2004-2008. Responsibility: Project leader.
- Research grant: Anti-inflammatory treatment to reduce atherosclerosis and acute myocardial ischemia. Swiss National Science Foundation, 2005 - 2007. Responsibility: Project leader.
- Research grant: Anti-Inflammatory Approaches to Reduce Ischemia-Reperfusion Injury during Acute Myocardial Infarction. Swiss National Science Foundation, 2008 - 2010. Responsibility: Project leader.
- Research grant: "AtheroRemo", Seventh Framework Program Theme FP7-Health-2007. 2008-2013. Responsibility: Project Leader and Work Package Coordinator.
- Research grant: "Role of inflammatory cytokines chemokines and soluble mediators in symptomatic carotid atherosclerotic disease" De Reuter Foundation 2009. Responsibility: Project Leader.
- Research grant: "Role of inflammatory cytokines chemokines and soluble mediators in symptomatic carotid atherosclerotic disease." Boninchi Foundation 2010. Responsibility: Project Leader.
- Research grant: "To reduce carotid plaque formation and vulnerability: participation of inflammatory factors (angiotensins, endocannabinoids, CRP) and novel therapies" Swiss-Brazil collaborative Project. Responsibility: Project Leader.
- Research grant: Selective anti-inflammatory treatments to reduce post-infarction heart failure. Swiss National Science Foundation, 2011 - 2013. Responsibility: Project leader.
- Research grant: Role of endocannabinoids in human carotid plaque vulnerability. Swiss Cardiology Society, 2011. Responsibility: Project leader.
- Research grant: Selective anti-inflammatory treatments to reduce post-infarction heart failure Novartis Foundation, 2011. Responsibility: Project leader.
- Research grant: "ATHERO-B-CELL", Seventh Framework Program Theme FP7-INNOVATION I HEALTH-F2-2013-602114, 2013-2018. Responsibility: Project Leader and Work Package Coordinator.

### **C. Scientific background.**

Prof. François Mach is one of the major Experts in Europe in cardiovascular diseases and, in particular, in atherosclerosis. His research work was developed on in vitro, animal models and human beings, focusing on the immunological aspects of the pathophysiology of atherosclerosis and its complications. He clarified the role of new mediators (such as cannabinoids, CD40 ligand, chemokines) in atherosclerosis and acute myocardial infarction and contributed to identify the immunomodulatory activities and anti-atherosclerotic treatments, such as statins.